Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy.
The aetiology of hepatic dysfunction in patients with HIV infection is multifactorial. Re-activation of hepatitis C infection, drug toxicity, and opportunistic infections are all potential causes. Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for the treatment of HIV infection. It is associated with a significant incidence of hepatotoxicity, usually occurring in the initial month of therapy. We report the case of a 49-year-old man who developed NVP-induced prolonged hepatotoxicity 5 months after commencing antiretroviral therapy.
Clarke
S
S
Department of Genito-Urinary Medicine, St James's Hospital, Dublin, Ireland.
Harrington
P
P
Condon
C
C
Kelleher
D
D
Smith
O P
OP
Mulcahy
F
F
D019380:Anti-HIV Agents / Q000009:adverse effects*; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000009:adverse effects*; D013997:Time Factors
D019380:Anti-HIV Agents; D019829:Nevirapine